Barinthus Biotherapeutics plc (BRNS)

NASDAQ: BRNS · IEX Real-Time Price · USD

2.429

-0.141 (-5.49%)

At close: Apr 25, 2024, 4:00 PM

2.440

+0.011 (0.46%)

After-hours: Apr 25, 2024, 4:13 PM EDT

Barinthus Biotherapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	0.8	44.7	0.27	4.82	6.85
Revenue Growth (YoY)	-98.21%	16580.22%	-94.44%	-29.57%	-
Gross Profit	0.8	44.7	0.27	4.82	6.85
Selling, General & Admin	39.84	6.39	25.12	10.48	2.67
Research & Development	44.87	42.35	20.37	14.39	29.84
Operating Expenses	84.72	48.74	45.49	24.87	32.51
Operating Income	-83.91	-4.04	-45.22	-20.05	-25.66
Interest Expense / Income	0.03	0.02	2.67	3.6	0.13
Other Expense / Income	-7.52	-4.93	3	-6.04	-5.07
Pretax Income	-76.42	0.87	-50.89	-17.61	-20.73
Income Tax	-3.08	-4.47	-0.03	0.1	0
Net Income	-73.35	5.34	-50.87	-17.71	-20.73
Shares Outstanding (Basic)	38	37	26	8	23
Shares Outstanding (Diluted)	38	38	26	8	23
Shares Change	0.57%	47.40%	227.59%	-66.32%	-
EPS (Basic)	-1.91	0.14	-1.96	-2.24	-883.27
EPS (Diluted)	-1.91	0.14	-1.96	-2.24	-883.27
Free Cash Flow	-56.34	-20.18	-33.73	-11.32	-18.81
Free Cash Flow Per Share	-1.47	-0.54	-1.30	-1.43	-0.80
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-10463.09%	-9.04%	-16873.51%	-415.81%	-374.94%
Profit Margin	-9145.51%	11.95%	-18979.48%	-367.27%	-302.84%
Free Cash Flow Margin	-7024.69%	-45.14%	-12585.45%	-234.83%	-274.74%
Effective Tax Rate	-	-513.32%	-	-	-
EBITDA	-69.64	6.43	-47.29	-13.8	-20.25
EBITDA Margin	-8682.92%	14.38%	-17643.66%	-286.31%	-295.86%
Depreciation & Amortization	6.76	5.54	0.94	0.21	0.35
EBIT	-76.39	0.89	-48.23	-14.01	-20.6
EBIT Margin	-9525.44%	1.99%	-17994.40%	-290.62%	-300.90%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).